In light of her professional success, Dr. Wang has been recognized with numerous accolades, such as 2022 Top Pathologist by Women in Medicine and 2024 Top Doctor by Philadelphia Magazine.
PHILADELPHIA, PA, July 26, 2024 /24-7PressRelease/ — Y. Lynn Wang has been selected for inclusion in Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Wang is a full professor and a distinguished medical director of molecular pathology at Fox Chase Cancer Center, where she has been serving since 2018. In this role, she provides clinical services, conducts groundbreaking research, handles administrative tasks, and imparts her extensive knowledge to medical trainees. Dr. Wang’s expertise in clinical molecular pathology, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma has significantly influenced these fields.
Dr. Wang conducted her post-graduate medical training at University of Pennsylvania and became board-certified pathologist right after her training. She started her physician-scientist career in 2002 when she joined Weill Cornell Medical College as an assistant professor and director of the laboratory. Subsequently, she was promoted to an associate professor in 2008 and stayed at Weill Conell until 2013.
The University of Chicago then recruited her as a professor and the founding Division Director of Genomic and Molecular pathology. Dr. Wang, as a first-generation immigrant, thus became the 1st Asian women who was raised to the full professor rank at this prestigious institution, and she was under 50. Between 2013 and 2018, she led her team who developed and launched the first ever next-gen sequencing-based cancer test in the Spring of 2014. This made U Chicago the only Institution in the Chicago area that offers advanced and comprehensive genomic testing until 2018. These tests placed the Institution at the forefront of personalized medicine.
In 2018, Dr. Wang was recruited by Incyte Corporation as the Executive Director of Translation Sciences. From 2018 to 2020, she also worked as a part-time pathologist at the Fox Chase Cancer Center and she then became full time in 2021.
Throughout her illustrious career, Dr. Wang has made significant contributions as an investigator/inventor. She has authored _80 publications, with her 2014 New England Journal of Medicine article being read ~70,000 times. She is considered the top 5% investigators by citations and has notably influenced the understanding and treatment of lymphoma and chronic lymphocytic leukemia. She holds several patents and has another one currently being prepared for commercial availability. Additionally, Dr. Wang has served as a consultant for various pharmaceutical companies.
Dr. Wang’s earlier academic journey includes earning a Doctor of Medicine in her native China in 1988. She later received a Doctor of Philosophy in molecular biology and biochemistry from Brandeis University in 1995. Additional educational pursuits to Dr. Wang’s credit include completing a fellowship in molecular genetic pathology in 1998 and a residency in pathology and laboratory medicine in 2002, both at the University of Pennsylvania. Moreover, she maintains physician licenses in Pennsylvania and holds board certification as a pathologist in clinical pathology and molecular genetic pathology through the American Board of Pathology.
Dr. Wang is an active member of various professional organizations, including the Association for Molecular Pathology, the American Society for Investigative Pathology, the American Society of Hematology, the U.S. and Canadian Academy of Pathology, and the Chinese American Hematologist and Oncologist Network. She was also an active member in the International BCR-ABL RQ-PCR Standardization Group and the Expert Panel for Genetic Testing Reference Materials Coordination Program at the Centers for Disease Control and Prevention.
In light of her professional success, Dr. Wang has been recognized with numerous accolades, such as 2022 Top Pathologist by Women in Medicine and 2024 Top Doctor by Philadelphia Magazine. She also received the Yao Yuan Award for Research Excellence in 2017.
Dr. Wang aims to publish more significant research in the future. She also envisions increasing the readership of her work, establishing more collaborations with academic and industrial partners, and securing additional research funding and philanthropic support for her CLL and lymphoma research before considering retirement in another decade.
About Marquis Who’s Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who’s Who in America®, Marquis Who’s Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who’s Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who’s Who® website, www.marquiswhoswho.com.
# # #
